Ignite Creation Date:
2024-05-06 @ 5:50 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05450965
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-02
First Post:
2022-06-30
Brief Title:
Study of PLK1 Inhibitor Onvansertib in Relapsed Small Cell Lung Cancer
Sponsor:
Taofeek Owonikoko
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
A Phase 2 Study of PLK1 Inhibitor Onvansertib in Relapsed Small Cell Lung Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer SCLC who have either not responded to or are unable to tolerate chemotherapy Onvansertib is a drug that inhibits polo-like kinase 1 PLK-1 an enzyme that is over-expressed in many cancer cells and is involved in cellular repair
Detailed Description:
This is a single arm two stage phase II study of onvansertib in patients with relapsed SCLC who have received not more than 2 lines of prior therapies The study will enroll 15 patients in stage I Enrolment into stage II will occur if two or more patients achieve objective response Subsequent enrolment into stage II will be by biomarker selection if the stage I accrual supports any of the three preliminarily nominated biomarkers ie TP53 mutation type SCLC-Y or MYC expression In order to establish the safety and tolerability of onvansertib at the dose of 15 mgm2 on D1-D14 of a 21-day cycle the first 6 participants will be closely monitored as a safety a run-in Full safety evaluation will be conducted after all 6 patients have completed at least 1 cycle of therapy A lower dose of onvansertib will be considered and schedule of onvansertib as per the planned dose modification strategy if during the safety run-in there are any deaths not clearly attributable to the underlying disease or extraneous causes or for Grade 4 hematologic or non-hematologic adverse events AEs occurring in 2 or more patients In the event that a dose de-escalation is necessary following the initial safety run-in cohort the run-in procedure will be repeated for the reduced dose level as described above The study will continue to enroll to stage I at the dose established to be safe from the safety run-in cohort Patients treated at the established dose in the safety run-in phase will count toward the total stage I accrual goal of 15 patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01CA273216-01 | NIH | None | httpsreporternihgovquickSearchR01CA273216-01 |